The healthcare industry is at a critical juncture, where every effort is being made to increase the effectiveness of care, while decreasing the financial burden on our system. With the introduction of BioTelemetry, we aim to lead in the advancement of mobile health monitoring by providing unmatched products and services to help healthcare professionals track and diagnose patients in a more efficient, accurate, and cost-effective manner. In April 2013, our predecessor company, CardioNet, Inc. (NASDAQ: BEAT), announced plans to adopt a holding company structure to more effectively facilitate our ongoing growth plans. With this change, our strategy is to achieve sustained long-term growth by solidifying our leadership position in remote cardiac monitoring, building a leading research services business, and identifying markets that would benefit from the application of our wireless platform and proprietary technology. We currently have four subsidiaries: CardioNet & Mednet- cardiac medical device & monitoring services, Braemar- cardiac manufacturing, Cardiocore- cardiac clinical research.